Search Bar & Filters
Found 14 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating molnupiravir, a study medicine designed to stop the COVID-19 virus from multiplying, to see if it can prevent severe illness from COVID-19 more effectively than a placebo in people who are at high risk. The focus is on non-hospitalized adults with COVID-19 who have certain health conditions or factors that increase their chance of severe illness, which can require hospitalization or lead to death. Participants will be randomly assigned to receive either 800 mg of molnupiravir orally every 12 hours for 5 days a total of 10 doses or a matching placebo on the same schedule. Some participants may also receive remdesivir as standard care if clinically appropriate. This is a phase 3, double-blind, placebo-controlled study comparing molnupiravir versus placebo. During the study, participants will be monitored for up to 29 days for outcomes such as hospitalization, death, and COVID-19-related medically attended visits. Researchers will assess adverse events and discontinuation due to side effects over approximately 5 months. Other measures include tracking symptom relief, changes in virus levels, and need for medical interventions. The total participation duration covers treatment and follow-up monitoring to evaluate safety and effectiveness.
Actively Recruiting
Researchers are evaluating elecoglipron, a drug administered orally once daily, for adults with type 2 diabetes mellitus T2DM who also have impaired kidney function and are receiving background treatment with dapagliflozin 10 mg, a sodium-glucose cotransporter 2 inhibitor SGLT2i. This phase III, randomized, double-blind study aims to assess the efficacy, safety, and tolerability of elecoglipron compared with placebo in this population, who are also on other glucose-lowering medications. Participants will be randomly assigned to receive either elecoglipron at one of two dose levels or a placebo, all given orally once daily alongside their background dapagliflozin treatment. The study uses a parallel-group design and will continue for 40 weeks, during which participants treatment adherence and response will be monitored closely. Throughout the study, participants will undergo regular assessments including measurements of hemoglobin A1c HbA1c from baseline to week 40, body weight, blood pressure, and fasting plasma glucose. Researchers will also track the time to initiation of any rescue medication and monitor for any hypoglycemic events. Safety and tolerability will be continuously evaluated during this period to understand the overall impact of elecoglipron compared to placebo.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the long-term effects of aleniglipron, an oral drug, in adults living with obesity or overweight and type 2 diabetes mellitus T2DM. This randomized, double-blind, placebo-controlled phase 3 study aims to assess the efficacy, safety, and tolerability of multiple doses of aleniglipron for chronic weight management in this population. Participants will be randomly assigned to receive either oral aleniglipron or a placebo once daily. The treatment period lasts for 76 weeks, during which participants will take the assigned medication regularly. The study includes several experimental arms receiving aleniglipron and one placebo arm to compare outcomes. During the study, participants will have assessments at baseline and week 76 to measure changes in body weight, waist circumference, HbA1c levels, blood pressure, triglycerides, and cholesterol. Researchers will track the percentage of participants achieving significant weight loss and HbA1c targets. Safety and tolerability will be monitored throughout the treatment period, with the total participation lasting approximately 76 weeks.
Actively Recruiting
Researchers are studying the safety and effectiveness of RTN-001, a modified release drug, in adults aged 18 to 75 years with uncontrolled and resistant hypertension, defined as systolic blood pressure SBP of 135 mm Hg or higher and diastolic blood pressure DBP of 80 mm Hg or higher. This Phase 2b trial is randomized, double-blind, and involves multiple centers. The study includes three main periods Screening, Run-in, and Treatment. During the trial, about 280 eligible participants will be randomly assigned equally into four groups to receive one of three doses of RTN-001 15 mg, 30 mg, or 45 mg or a matching placebo. The treatment lasts for 12 weeks. After the treatment period ends, participants will have an off-treatment follow-up visit two weeks later to assess their condition. Participants will be involved in various assessments throughout the study, including blood pressure measurements taken at multiple time points during and after treatment. Researchers will monitor changes in systolic and diastolic blood pressure using office measurements, central blood pressure readings, and ambulatory monitoring. Safety and efficacy will be evaluated through these repeated measures, and adherence to the study drug will be tracked. The total participation includes screening, run-in, treatment, and follow-up visits spanning several months.
Actively Recruiting
Researchers are investigating the long-term effectiveness, safety, and tolerability of once-daily oral ASC30 compared to a placebo in adults with obesity or overweight and type 2 diabetes mellitus T2DM. This Phase III, global, randomized, double-blind, placebo-controlled study seeks to understand how different maintenance doses of ASC30 impact these participants over time. Participants will be randomly assigned to receive one of three doses of oral ASC30 tablets or matching placebo tablets once daily. The study compares these groups to evaluate the effects of ASC30 on weight and metabolic health over a 72-week period. Treatment is administered daily by mouth throughout the study. During participation, individuals will undergo regular assessments including measurements of body weight, blood sugar control HbA1c and fasting glucose, blood pressure, cholesterol, triglycerides, insulin levels, waist circumference, and body mass index. The main outcome is the percent change in body weight from the start to week 72. Safety and tolerability will be closely monitored, and the entire study duration spans about 72 weeks from baseline to final evaluation.
Actively Recruiting
Researchers are conducting a global Phase III clinical trial to evaluate the long-term effects of ASC30, an oral medication taken once daily, in adults with obesity or overweight who also have weight-related health conditions but do not have type 2 diabetes. The study aims to compare the efficacy, safety, and tolerability of three different maintenance doses of ASC30 against a placebo. This randomized, double-blind, placebo-controlled trial focuses on assessing body weight changes and related health measures over a lengthy period. Participants in this trial will be randomly assigned to one of four groups three groups receive different doses of ASC30 tablets daily, and one group receives matching placebo tablets daily. The treatment period is planned to last 72 weeks, during which participants will take their assigned oral tablets once a day. The study carefully monitors participants throughout the treatment phase to evaluate the effects of the medication compared to placebo. During the trial, participants will undergo regular assessments including measurements of body weight, waist circumference, blood pressure, blood glucose, cholesterol, insulin, and other metabolic markers from baseline through week 72. Researchers will also track safety and tolerability over this period. Participants can expect scheduled visits and evaluations to monitor changes in their health and response to the study medication over the roughly 1.5-year treatment duration.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of elecoglipron compared with oral semaglutide in adults with type 2 diabetes mellitus T2DM who have an increased cardiovascular risk. This study focuses on patients whose diabetes is not adequately controlled with lifestyle changes or stable glucose-lowering medications. The trial is a Phase III, randomized, open-label, parallel-group study sponsored by AstraZeneca. Participants will be randomly assigned to receive either elecoglipron or semaglutide, both administered orally once daily at specified doses. The treatment period lasts up to 52 weeks, during which the effects of these medications on blood sugar control and other health measures will be assessed. Throughout the study, participants will undergo regular evaluations including measurements of hemoglobin A1c HbA1c, body weight, and blood pressure at baseline and at 52 weeks. Researchers will monitor changes in these parameters to assess the impact of the treatments. Safety and tolerability will also be closely followed during the trial period.
Actively Recruiting
Researchers are identifying and characterizing patients with Type 2 Diabetes Mellitus T2DM to support participation in current or future clinical studies focused on this condition. The study aims to observe trends in key medications used alongside diabetes treatments across various geographical areas, helping to better understand patient profiles and treatment patterns. Participants with T2DM who are inadequately managed by lifestyle changes alone or stable on glucose-lowering medications for at least 45 days will be observed. The study involves a single visit where assessments include collecting about 2 mL of blood and recording medical history, medication use, and HbA1c levels. This observational study does not administer treatments but gathers important health information. During the study visit, participants will provide demographic details, medical and surgical history, current medications, and blood samples to measure HbA1c levels. Researchers will also note referrals to ongoing or future T2DM studies. Participation requires signed consent and willingness to follow study procedures. The study concludes after the single visit, with no further follow-up required.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tezepelumab in adults with moderate to very severe chronic obstructive pulmonary disease COPD who are already receiving inhaled maintenance therapy and have experienced recent COPD exacerbations. This Phase 3, multicenter, randomized, double-blind, placebo-controlled study aims to understand how tezepelumab impacts COPD outcomes compared to a placebo. Participants will receive monthly subcutaneous injections of one of two doses of tezepelumab or a matching placebo. The treatment period lasts a minimum of 52 weeks and up to 76 weeks. Following treatment, there is a 12-week safety follow-up without active treatment to monitor participants. Throughout the study, participants will be monitored regularly to assess lung function, COPD symptoms, and exacerbation rates. Researchers will collect data on lung function tests, symptom questionnaires, and exacerbation frequency up to 76 weeks. Blood samples will be taken to study drug levels and immune responses. The total participation time for each individual includes the treatment period plus the safety follow-up phase.
Actively Recruiting
Researchers are evaluating the effects of tozorakimab, a drug given by injection under the skin, in adults with uncontrolled asthma who are already using medium to high doses of inhaled corticosteroids. This phase IIb study is designed to find the right dose and assess how safe and effective tozorakimab is for reducing severe asthma attacks over a period of 26 to 52 weeks. Participants will be randomly assigned to receive one of two doses of tozorakimab or a placebo, all given subcutaneously. The study is double-blind, meaning neither participants nor researchers know who receives which treatment. The treatment period lasts up to 52 weeks with regular monitoring. The study will measure asthma exacerbation rates, lung function changes, asthma control, quality of life, and drug levels in the blood. During the trial, participants will complete daily asthma diaries to track symptoms and medication use, and attend visits for lung function tests, questionnaires, and blood samples. Safety and antibody responses to the drug will be monitored throughout. Participation lasts up to about one year, including screening and treatment, with regular visits to assess health and response to the study drug.
1-10 of 14
1